Company
Radiopharm Theranostics Ltd
ASX:RAD
Radiopharm Theranostics is a clinical-stage biotech company revolutionizing cancer care through the development of first-in-class radiopharmaceuticals. The company is advancing a pipeline of distinct radiopharmaceutical technologies for novel oncology targets—avoiding "me-too" targets like Prostate-Specific Membrane Antigen (PSMA), Fibroblast Activation Protein (FAP) or Somatostatin Receptor 2 (SSTR2).
101 stories · page 1 of 6
Radiopharm Theranostics advances clinical trials towards multiple inflection points
RAD's radiopharmaceutical assets – already in advanced clinical trials – have unlimited potential because they can be used instead of or in combination with other cancer treatments. They also have a role in diagnosis.